shutterstock_399778786_paul_brady_photography

Paul Brady Photography / Shutterstock.com

9 November 2023Big PharmaMuireann Bolger

FTC challenges more than 100 pharma patents

Commission targets big pharma companies over ‘improper listings’ | Agency argues that alleged inaccuracies may delay lower-cost generic drug competition, stall drug development, and stifle innovation.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

More on this story

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility